SIBN logo

SI-BONE, Inc. Stock Price

NasdaqGM:SIBN Community·US$723.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

SIBN Share Price Performance

US$16.80
-1.63 (-8.84%)
US$25.00
Fair Value
US$16.80
-1.63 (-8.84%)
32.6% undervalued intrinsic discount
US$24.93
Fair Value
Price US$16.80
AnalystConsensusTarget US$24.93
AnalystLowTarget US$18.00
AnalystHighTarget US$31.60

SIBN Community Narratives

·
Fair Value US$25 32.8% undervalued intrinsic discount

Expanding Minimally Invasive Procedures Will Open US And European Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$18 6.7% undervalued intrinsic discount

Rising US Reimbursement Risk Will Curb Opportunities Yet Allow Recovery

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$31.6 46.8% undervalued intrinsic discount

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$25
32.8% undervalued intrinsic discount
Profit Margin
12.49%
Future PE
40.89x
Price in 2028
US$30.49

Trending Discussion

Updated Narratives

SIBN logo

SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential

Fair Value: US$18 6.7% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

Fair Value: US$31.6 46.8% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Expanding Minimally Invasive Procedures Will Open US And European Markets

Fair Value: US$25 32.8% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and good value.

2 Risks
3 Rewards

SI-BONE, Inc. Key Details

US$206.2m

Revenue

US$42.1m

Cost of Revenue

US$164.1m

Gross Profit

US$180.8m

Other Expenses

-US$16.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.38
79.59%
-8.10%
19.9%
View Full Analysis

About SIBN

Founded
2008
Employees
376
CEO
Laura Francis
WebsiteView website
si-bone.com

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Recent SIBN News & Updates

Narrative Update Jun 06

SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential

Analysts kept their $18.00 price target for SI-BONE steady, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and forward P/E, without a clear shift in overall conviction. What's in the News SI-BONE issued raised earnings guidance for 2026, with worldwide revenue now expected in a range of $230 million to $233 million, compared with prior guidance of $228.5 million to $232.5 million.
Narrative Update May 22

SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside

Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).

Recent updates

No updates